MONOSODIUM GLUTAMATE ANHYDROUS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C5H7NO4.Na.H
Molecular Weight	169.1111
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of MONOSODIUM GLUTAMATE ANHYDROUS

SMILES

[H+].[Na+].N[C@@H](CCC([O-])=O)C([O-])=O

InChI

InChIKey=LPUQAYUQRXPFSQ-DFWYDOINSA-M

InChI=1S/C5H9NO4.Na/c6-3(5(9)10)1-2-4(7)8;/h3H,1-2,6H2,(H,7,8)(H,9,10);/q;+1/p-1/t3-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C5H7NO4
Molecular Weight	145.1134
Charge	-2
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H
Molecular Weight	1.0079
Charge	1
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Glutamic acid is a non-essential aminoacid used in biosynthesis of proteins. Besides being a building block of proteins, glutamic acid plays a principal role in neural activation. Glutamate is also responsible for the umami (savory) flavor of certain foods. In medicine, glutamate is used as a metabolic supplemnet in patients undergoing coronary surgery.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glutamate [NMDA] receptor	Agonist
Glutamate receptor ionotropic kainate	Agonist
Glutamate receptor ionotropic AMPA	Agonist
Metabotropic glutamate receptor 1	Agonist

Conditions

Condition	Modality	Highest Phase	Product
Nerve damage	Preventing	Phase III	Unknown
Delayed gastric emptying	Primary	Not Provided	Unknown
Postoperative heart failure	Palliative	Phase III	Unknown

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B1-00649	http://www.3bsc.com/index/pro_info.php?id=20861
3B Scientific (Wuhan) Corp	3B3-006381	http://www.3bsc.com/index/pro_info.php?id=28289
AA Blocks	AA00375U	http://www.aablocks.com/goods/Goods/detail?id=AA00375U
Aaron Chemicals	AR0037XM	http://www.aaronchem.com/56-86-0
abcr GmbH	AB116926	http://www.abcr.com/shop/en/AB116926

Showing 1 to 5 of 94 entries

Previous1 2 3 4 5…19Next

PubMed

Show entries

Title	Date	PubMed
Cycling treatment of anaerobic and aerobic incubation increases the content of gamma-aminobutyric acid in tea shoots.	2001	11354609
Alterations of amino acids and monoamine metabolism in male Fmr1 knockout mice: a putative animal model of the human fragile X mental retardation syndrome.	2001	12018775
Conversion of the ion selectivity of the 5-HT(3a) receptor from cationic to anionic reveals a conserved feature of the ligand-gated ion channel superfamily.	2001 Apr 6	11139582
Mechanisms of neurodegeneration in amyotrophic lateral sclerosis.	2001 Dec	11724913
Effects of glial glutamate transporter inhibitors on intracellular Na+ in mouse astrocytes.	2001 Mar 2	11222991

Showing 1 to 5 of 50 entries

Previous1 2 3 4 5…10Next

Patents

Sample Use Guides

In Vivo Use Guide

As a dietary supplement for taste improvement, glutamate is administered orally with food. Glutamate is administered intravenously in patients undergoing coronary artery bypass surgery.

Route of Administration: Other

In Vitro Use Guide

To study binding of glutamate to AMPA and Kainate ion channels, [3H]APMA and [3H]kainic acid were used as a radioligands.